US giant Johnson & Johnson (J&J, NYSE: JNJ) has committed to investing over USD 55 billion over the next four years in the United States, allocated to manufacturing, research and development, and technology. This represents a 25% increase compared to the previous four years, building on the company’s increased investment levels in the US since the 2017 Tax Cuts & Jobs Act.
North Carolina Facility and Job Creation
The initiative begins with the groundbreaking of a high-tech facility in North Carolina, set to boost manufacturing capacity for next-generation drugs targeting cancer, immune-mediated diseases, and neurological disorders. The project will support 5,000 jobs during construction and create over 500 positions in the state, which will receive USD 3 billion in benefits over the first 10 years of operation.
Expansion of Manufacturing and R&D Infrastructure
In addition to the North Carolina facility, J&J plans to establish three new advanced manufacturing facilities and expand several existing sites across its Innovative Medicine and MedTech businesses. The company will also make significant investments in R&D infrastructure to develop treatments in areas such as oncology, neuroscience, immunology, and cardiovascular disease, alongside advancing robotic surgery technologies.
Technology Investments and Operational Enhancements
J&J is ramping up technology investments to accelerate drug discovery and development, support workforce training, and enhance business operations. These investments aim to make the drug development process faster and more efficient, ultimately delivering life-saving and life-changing treatments to patients globally.-Fineline Info & Tech
Leave a Reply